GlycoMimetics

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q2 2024

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Earnings data Q2 2025

GlycoMimetics reports strong Q4 performance and optimistic clinical advancements

GlycoMimetics delivered a robust performance in Q4 2022, driven by positive clinical outcomes and strategic financial decisions. The company's focus on uproleselan and promising interim utility analysis sets a solid foundation for future growth. While challenges like managing expenses and meeting trial milestones exist, GlycoMimetics is well-positioned to capitalize on opportunities in the biopharmaceutical sector.

GlycoMimetics excels in AML trials, secures funding for future growth

GlycoMimetics showcased strong performance in both clinical trials and financial standing, positioning the company well for future growth.
While challenges in managing expenses and navigating industry complexities exist, opportunities for expansion and innovation through partnerships are promising.

GlycoMimetics advances clinical trials and secures funding until late 2024

GlycoMimetics showcased strong progress in their clinical trials and financial stability during the Q2 2023 Earnings Call. With FDA clearance for Phase III uproleselan study and a cash runway until late 2024, the company is well-positioned for future growth. Challenges include successful trial execution and maintaining financial discipline.

GlycoMimetics progresses in AML trials, eyes positive Phase III results

GlycoMimetics demonstrated strong performance in advancing its clinical pipeline, with a focus on uproleselan in AML.
While facing challenges like delays in studies and increased expenses, the company remains optimistic about future prospects.
Opportunities lie in presenting data at conferences, exploring market expansion, and anticipating positive Phase III results by Q2 2024.

GlycoMimetics reports progress in trials and financial strength for growth

GlycoMimetics' Q4 2023 earnings call showcased positive clinical trial outcomes, strong financial standing, and a strategic focus on addressing unmet medical needs. The company's upcoming milestones, including the Phase III trial results and NDA submission, indicate promising growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.

GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023

Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the treatment of relapsed/refractory AML patients should continue as planned. Last event to trigger final results from the phase 3 study, using uproleselan in combination with chemotherapy for the treatment of relapsed/refractory AML patients expected 1st half of 2024.

GlycoMimetics: Stock Price Drop Brings Great Speculative Trade Opportunity

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2023 at 12:50 p.m. ET. A live webcast of the panel presentation will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations. An archived recording will be available for 30 days following the event.

GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference

The stock price of GlycoMimetics Inc (NASDAQ: GLYC) dropped by 62.47% in the most recent trading session. This is why.

GLYC Stock: 62.47% Plummet Explanation

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the independent Data Monitoring Committee (DMC) reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML) and recommended the study should continue to the originally planned final overall survival event trigger.

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

Blue Water Vaccines

Iris Energy Ltd

Penny stocks to watch this week. The post Penny Stocks To Buy After CPI Report?

Penny Stocks To Buy After CPI Report? 3 To Watch Today

GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30%. Small research trial sizes have delivered exceptional results, with the U.S. FDA engaging in an Interim Utility Analysis of the company's uproleselan Phase 3 study.

GlycoMimetics: A Cancer-Cure Lottery Ticket Grabbing My Attention

Acasti Pharma

Eiger BioPharmaceuticals

Maris-Tech

Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch

ROCKVILLE, Md.--( BUSINESS WIRE )--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced results from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemia (AML). These results were presented at the 64th American Society of Hematology (ASH) Annual Meeting.

GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright

GlycoMimetics stock price jumped on November 9. Good cancer survival results may have lengthened the timeline for a trial readout.

GlycoMimetics Could Surge If Q1 Data Readout Is Positive

GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Christian Dinneen-Long - Company Counsel Harout Semerjian - President and Chief Executive Officer Brian Hahn - Senior Vice President and Chief Financial Officer Bruce Johnson - Senior Vice President and Chief Commercial Officer Edwin Rock - Chief Medical Officer Conference Call Participants Edward White - H.C. Wainwright Operator Good morning and thank you for joining the GlycoMimetics Q3 2022 Earnings Call.

GlycoMimetics, Inc. (GLYC) Q3 2022 Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022

GlycoMimetics to Participate in Two Upcoming Investor Conferences

GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting

GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022

GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlycoMimetics (GLYC) Upgraded to Buy: Here's Why

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET. An archived recording of the presentation will be available for 90 days on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations. About GlycoMimetics, Inc. GlycoMimetics is a clinical-stage b

GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

What Makes GlycoMimetics (GLYC) a New Buy Stock

GlycoMimetics, Inc. (NASDAQ:GLYC ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Christian Dinneen-Long - Company Counsel Harout Semerjian - Chief Executive Officer Brian Hahn - Chief Financial Officer Bruce Johnson - Chief Commercial Officer Conference Call Participants Boris Peaker - Cowen and Company Roger Song - Jefferies Steve Bersey - H.C. Wainwright Operator Good morning, and thank you for joining the GlycoMimetics Q2 2022 earnings call.

GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q2 2022 Results - Earnings Call Transcript

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the second quarter ended June 30, 2022. Cash and cash equivalents as of the end of the quarter were $60.2 million. “During second quarter, we made strides in advancing our transformation from a research company to a commercially focused organization and are encouraged by the continued progress of our pivotal Phase 3 trial of uproleselan in relapsed/refractory AML,” said Ha

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter financial results on Wednesday, August 3, 2022, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the “Investors” tab on the

GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the Jefferies 2022 Healthcare Conference, on June 8th, in New York, NY. Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Roger Song, M.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at https://ir.glycomimetic

News for GlycoMimetics Stock (GLYC)